Description - 100 test kit
The
hTSH [125I] IRMA system provides a direct quantitative in
vitro determination of human thyroid stimulating hormone (hTSH) in human
serum. hTSH can be assayed in the range 0-100 µIU/ml using 100 or 200 µl
serum sample. Each kit contains materials sufficient for 100 assay tubes
permitting the construction of one standard curve and the assay of 40
unknowns in duplicate.
Introduction
The
thyroid stimulating hormone (thyrotropin or TSH) is a glycoprotein with
a molecular weight of 28000, secreted by the adenohypophysis. Like other
glycoprotein hormones (FSH, LH and HCG), TSH contains two different
subunits, an alpha- and a ß-chain, linked by noncovalent bounds. The
primary structure of alpha subunits of TSH and of the gonadotropins is
the same, whilst their ß subunits are different. The ß subunits are
responsible for the immunological and biological specificity of these
hormones.
The
synthesis and the release of TSH are controlled by the circulatory level
of thyroid hormones; triiodothyronine (T3) and thyroxine (T4) and by the
hypothalamic thyrotropin releasing hormone (TRH). Thyroid hormones
regulate the secretion of TSH by a negative feedback mechanism. An
elevation of T3 or T4 will suppress, and their fall will, in turn,
increase the level of thyroid stimulating hormone in serum. The
increased concentration of TSH in the serum is the earliest and best
indicator of primary hypothyroidism.
The
determination of TSH by immunoassay methods plays a crucial role in the
diagnosis of thyroid disorders and in the evaluation of the functional
integrity of the hypothalamic-pituitary axis.
The
outstanding sensitivity of the present hTSH IRMA system makes it
particularly suitable for the measurement of subnormal thyroid
stimulating hormone levels, a key to both the diagnosis and treatment
follow up of hyperthyroid patients.
Principle of method
The technology
uses two high affinity monoclonal antibodies in an immunoradiometric
assay (IRMA) system. It offers an increased level of sensitivity and
specificity compared with conventional RIA methods.
The 125I
labelled signal-antibody binds to an epitope of the hTSH molecule which
is different from that recognised by the unlabelled capture-antibody.
The two antibodies react simultaneously with the antigen present in
standards or samples, which leads to the formation of a capture
antibody - antigen - signal antibody complex, also referred to as a
“sandwich”.
Standards and samples are incubated with a mixture of the antibodies at
room temperature. At the end of a 45 minutes incubation period (no need
for a shaker), magnetic immunosorbent (MIS) is added in excess. MIS
particles selectively bind the hTSH – signal antibody – capture
antibody complex and settle out in a magnetic field. A wash step is
critical to reducing non-specific binding to a minimum for increased
low-end precision.
The
concentration of antigen is directly proportional to the radioactivity
measured in test tubes. By constructing a calibration curve plotting
binding values against a series of calibrators containing known amount
of thyroid stimulating hormone, the unknown concentration of hTSH in
patient samples can determined.
Contents of the kit
|
1 bottle |
TRACER, ready to use
21 ml, containing < 900 kBq 125I-signal and capture
antibody in buffer with red dye and 0.1% NaN3. |
|
8 vials |
STANDARD, ready to use
1.5 ml per vial, containing 0 (S0), 0.06 (S0.06),
0.15 (S0.15), 0.6 (S0.6), 2.5 (S2.5),
15 (S15), 50 (S50) and 100 (S100)
µIU/ml hTSH (WHO 2nd IRP 80/558) in serum with 0.1%
NaN3 |
|
2 vials |
CONTROL SERUM low (CI) and high (CII)
1.5 ml, containing 0.1% NaN3
The concentration of the control serum is specified in
the quality certificate enclosed. |
|
1 bottle |
MAGNETIC IMMUNOSORBENT (MIS), ready to use. DO NOT FREEZE!
55 ml, containing paramagnetic particles in buffer with 0.1% NaN3. |
|
1 bottle |
WASH BUFFER CONCENTRATE.
20 ml, containing 0.1% NaN3. See Preparation of
reagents |
|
1 pc |
Quality certificate |
|
1 pc |
Pack leaflet |
Materials, tools and equipment required
Distilled water
Round bottom polystyrene or polypropylene test tubes, about 12 x 75 mm.
Precision pipettes (100, 200, 500 and 1000 µl)
Vortex mixer
Rack and magnetic separator
Gamma counter
Absorbent tissue
Recommended
tools and equipment
Repeating pipettes (e.g. Eppendorf)
Dispenser with 1-L reservoir (instead of the 1 ml pipette)
Specimen collection and storage
Serum
samples can be prepared according to common procedures used routinely in
clinical laboratory practice. Samples can be stored at 2-8 °C if the
assay is carried out within 24 hours, otherwise aliquots should be
prepared and stored deep frozen (-20 °C). Frozen samples should be
thawed and thoroughly mixed before assaying. Repeated freezing and
thawing should be avoided. Do not use lipemic, hemolyzed or turbid
specimens.
Preparation of reagents, storage
Add the
wash buffer concentrate (20 ml) to 200ml distilled water to obtain 220
ml wash solution. Upon dilution store at 2-8 °C until expiration.
Store
the rest of reagents between 2-8 °C after opening. At this temperature
each reagent is stable until expiry date. The actual expiry date is
given on the package label and in the quality certificate.
CAUTION!
Equilibrate all reagents and serum samples to room temperature. Mix all
reagents and samples thoroughly before use. Avoid excessive foaming.
The Way of Use
The
assay can be used in different procedures. There are two options for
running the assay. The procedures are labelled as “A” & “B”. Patient
sample values and expected values are the same for both procedures.
OPTION “A”: The Basic Procedure
It is
very economical on sample consumption. Only 100 µl sample volume is
needed. The sensitivity attainable is 0.015 µIU/ml. At the expiry date
of the kit the analytical sensitivity is 0.04 µIU/ml. When the kit has
less then 3 weeks to its expiration standard 0.06 µIU/ml can be omitted.
However if sample consumption is not critical we recommend you OPTION B.
Standard solution 50 µIU/ml can also be omitted if the curve-fitting
algorithm of the gamma counter gives similar results with or without
this point.
OPTION “B”: The Hyper Sensitive Method
It
works in the same way as OPTION A except the sample volume, which is 200
µl. The sensitivity attainable is 0.008 µIU/ml. At the expiry date of
the kit the analytical sensitivity is 0.03 µIU/ml.
OPTION A - The Basic Procedure
(For a quick
guide, refer to Table 1.)
|
1 |
Dilute the wash buffer concentrate appropriately. |
|
2 |
Equilibrate reagents and samples to room temperature
before use. (Cold reagents will slow down the reaction and
warming up rate will be different from tube to tube.) |
|
3 |
Label test tubes in duplicate for each standard (0 -100
µIU/ml), control serum and patient samples. |
|
4 |
Homogenize all reagents and patient samples by gentle
mixing. Avoid foaming. |
|
5 |
Pipette 100 µl of standards, control and patient samples
into the bottom of labelled tubes. |
|
6 |
Pipette 200 µl of tracer into each tube. Total count
tubes should be set aside for counting. |
|
7 |
Incubate tubes for 45 minutes at room temperature (20–28
°C). |
|
8 |
Vigorously shake and swirl the bottle containing magnetic
immunosorbent until homogeneity is achieved. Add 500 µl MIS to
each tube. Swirl the bottle of MIS after every 15-20 tubes. |
|
9 |
Thoroughly vortex mix all tubes, and incubate them for 15
minutes at room temperature. |
|
10 |
Attach the rack on to the magnetic separator base and
ensure that every tube is in contact with the base plate. Let
the MIS particles settle for 5 minutes. Do not remove the rack
from the separator base after the separation of the solid and
liquid phases. Pour off and discard the supernatant. Keeping the
separator inverted, place the tubes on a pad of absorbent tissue
and allow to drain for 2 minutes. |
|
11 |
Return the separator to an upright position and add 1.0
ml of washing solution to each tube. For more comfort and
precision, it is recommended to use either a repeating pipette
(e.g. Eppendorf-pipette) or a dispenser with bottle for the
addition of washing solution. |
|
12 |
Vortex mix each tube thoroughly and repeat Step 10.
Intense vortexing is required. |
|
13 |
Count each tube for at least 60 seconds in a gamma
counter. |
|
14 |
Calculate the TSH concentrations of the samples as
described in Calculation of results or use special
software. |
Table
1. Assay Protocol, Pipetting Guide - for OPTION A
All volumes are in microliters (µl).
|
Tube |
Total |
Standard |
Sample |
Control |
|
Standard |
|
100 |
|
|
|
Sample |
|
|
100 |
|
|
Control |
|
|
|
100 |
|
Tracer |
(200) |
200 |
200 |
200 |
|
Vortex
mix
Incubate for 45 minutes at room temperature |
|
Magnetic immunosorbent |
|
500 |
500 |
500 |
|
Vortex
mix
Incubate for 15 minutes at room temperature |
|
Place
the tubes on the magnetic separator for 5 minutes. |
|
Decant the fluid and blot on filter paper |
|
Wash
Buffer |
|
1000 |
1000 |
1000 |
|
Vortex
mix |
|
Place
the tubes on the magnetic separator for 5 minutes. |
|
Decant the fluid and blot on filter paper |
|
Count
radioactivity (60 sec/tube) |
|
Calculate the results |
Characterization of the assay for OPTION A

Figure 1.
OPTION A Typical standard curve corresponding to Table 2.
(Do not use to calculate sample values!)
Table 2.
Typical assay data for OPTION A
| |
CPM
1 |
CPM
2 |
CPM
mean |
B/T % |
|
Total |
411 237 |
402 625 |
406 931 |
- |
|
S0 (NSB) |
117 |
97 |
107 |
0.026 |
|
S0.06 |
297 |
241 |
269 |
0.066 |
|
S0.15 |
518 |
572 |
545 |
0.134 |
|
S0.6 |
1 850 |
1 924 |
1 887 |
0.464 |
|
S2.5 |
7 602 |
7 736 |
7 669 |
1.88 |
|
S15 |
45 678 |
44 718 |
45 198 |
11.11 |
|
S50 |
132 951 |
131 243 |
132 097 |
32.46 |
|
S100 (Bmax) |
227 699 |
229 841 |
228 770 |
56.22 |
|
CI |
1 158 |
1 046 |
1 102 |
0.31 |
|
CII |
59 101 |
57 811 |
58 456 |
19.4 |
Sensitivity
The
analytical sensitivity or minimum detectable limit is calculated by
the interpolation of the mean counts of zero standard plus 2 standard
deviation from the standard curve. Determination was carried out using
20 replicates of zero standard response.
The value of
analytical sensitivity is 0.015 µIU/ml measured using fresh tracer.
The
functional sensitivity is a measure of the hTSH concentration that
is significantly different from zero as determined by the inter-assay
precision profile (22% CV).
The value of
functional sensitivity is: 0.09 µIU/ml.
Hook effect
There is no
high dose hook effect up to an hTSH concentration 500 µIU/ml.
Precision
The
within-assay precision was determined with 15 replicates within a single
run, the between-assay precision was estimated in 15 independent runs
carried out in duplicates. CV values are summarized below:
Table 3/1.
| |
intra-assay |
|
No. |
mean (µIU/ml) |
CV % |
|
1 |
0.207 |
5.8 |
|
2 |
0.737 |
2.8 |
|
3 |
1.01 |
3.4 |
|
4 |
1.19 |
2.6 |
|
5 |
1.89 |
2.9 |
|
6 |
3.31 |
1.6 |
|
7 |
6.77 |
1.2 |
The
between-assay (inter-assay) precision was determined using pooled human
serum samples in independent assay runs. The number of measurements on a
sample was a function of sample volume available. Three different
operators took part in the investigation process and four different
tracer batches were used at different ages of the reagents. Four
different lots of MIS were used to determine the inter-assay precision
profile. Results are presented below.
Table 3/2.
| |
|
inter-assay |
|
sample No. |
number of assay runs |
mean (µIU/ml) |
CV % |
|
1 |
18 |
0.049 |
33.8 |
|
2 |
18 |
0.079 |
25.4 |
|
3 |
19 |
0.090 |
15.1 |
|
4 |
11 |
0.095 |
17.1 |
|
5 |
20 |
0.124 |
14.1 |
|
6 |
19 |
0.143 |
13.1 |
|
7 |
19 |
0.196 |
8.3 |
Linearity – dilution test
Individual human serum samples were diluted with the zero standard of
the kit. The diluted samples were measured according to kit protocol.
Table 4.
|
sample
No. |
dilution factor |
expected µIU/ml |
observed µIU/ml |
recovery
% |
|
1 |
1 |
|
18.02 |
|
|
1 |
2.03 |
8.89 |
8.62 |
97.0 |
|
1 |
4.10 |
4.39 |
4.38 |
99.7 |
|
1 |
8.32 |
2.17 |
2.14 |
98.9 |
|
2 |
1 |
|
33.51 |
|
|
2 |
2.00 |
16.78 |
16.06 |
95.7 |
|
2 |
3.98 |
8.42 |
7.96 |
94.5 |
|
2 |
7.97 |
4.21 |
3.93 |
93.5 |
|
3 |
1 |
|
34.83 |
|
|
3 |
2.00 |
17.43 |
16.81 |
96.4 |
|
3 |
3.99 |
8.74 |
8.91 |
102.0 |
|
3 |
7.95 |
4.38 |
4.15 |
94.9 |
|
4 |
1 |
|
28.74 |
|
|
4 |
1.99 |
14.46 |
14.31 |
98.9 |
|
4 |
3.97 |
7.25 |
7.53 |
103.9 |
|
4 |
7.90 |
3.64 |
3.85 |
105.8 |
|
5 |
1 |
|
27.02 |
|
|
5 |
2.00 |
13.49 |
12.47 |
92.5 |
|
5 |
4.03 |
6.70 |
6.36 |
94.9 |
|
5 |
8.05 |
3.36 |
3.32 |
98.8 |
|
6 |
1 |
|
44,68 |
|
|
6 |
2.00 |
22.37 |
21.10 |
94.3 |
|
6 |
3.99 |
11.21 |
10.40 |
92.8 |
|
6 |
7,99 |
5.59 |
5.19 |
92.8 |
|
7 |
1 |
|
25.17 |
|
|
7 |
2.01 |
12.49 |
12.10 |
96.8 |
|
7 |
4.06 |
6.20 |
5.96 |
96.2 |
|
7 |
7.65 |
3.29 |
2.90 |
88.1 |
|
8 |
1 |
|
7.61 |
|
|
8 |
2.00 |
3.80 |
3.70 |
97.1 |
|
8 |
4.03 |
1.89 |
1.78 |
94.2 |
|
8 |
8.11 |
0.939 |
0.869 |
92.6 |
|
9 |
1 |
|
109.36 |
|
|
9 |
2.00 |
54.6 |
51.94 |
95.1 |
|
9 |
4.03 |
27.12 |
25.22 |
93.0 |
|
9 |
8.12 |
13.47 |
12.51 |
92.9 |
|
10 |
1 |
|
42.41 |
|
|
10 |
1.99 |
21.28 |
20.63 |
97.0 |
|
10 |
3.98 |
10.65 |
10.25 |
96.2 |
|
10 |
8.02 |
5.29 |
5.25 |
99.2 |
Recovery – addition test
Individual
human serum samples were spiked with known amount of an elevated stock
sample. Recovery % is to be interpreted as = (observed-base)/added*100.
The results are summarised below.
Table 5.
|
sample |
base
µIU/ml |
added
µIU/ml |
expected µIU/ml |
observed µIU/ml |
recovery
% |
|
1 |
8.33 |
17.27 |
25.61 |
25.48 |
99.3 |
|
2 |
7.36 |
18.72 |
26.07 |
25.39 |
96.3 |
|
3 |
8.34 |
18.57 |
26.90 |
26.66 |
98.7 |
|
4 |
8.98 |
16.39 |
25.37 |
25.00 |
97.7 |
|
5 |
5.18 |
18.01 |
23.19 |
20.84 |
86.9 |
|
6 |
5.38 |
15.83 |
21.20 |
20.54 |
95.8 |
|
7 |
10.22 |
15.79 |
26.02 |
26.22 |
101.3 |
|
8 |
14.44 |
13.42 |
27.86 |
27.46 |
97.0 |
|
9 |
10.02 |
13.57 |
23.59 |
22.82 |
94.3 |
|
10 |
0.750 |
14.35 |
15.10 |
14.61 |
96.6 |
|
11 |
1.46 |
14.71 |
16.17 |
15.90 |
98.2 |
|
12 |
0.921 |
14.39 |
15.31 |
14.44 |
94.0 |
|
13 |
0.011 |
2.66 |
2.67 |
2.80 |
104.9 |
|
14 |
0.013 |
2.70 |
2.72 |
2.95 |
108.7 |
|
15 |
0.029 |
2.73 |
2.76 |
3.03 |
109.9 |
|
16 |
0.058 |
2.65 |
2.71 |
3.20 |
118.5 |
|
17 |
0.102 |
3.62 |
3.72 |
4.05 |
108.9 |
|
18 |
0.053 |
2.74 |
2.79 |
2.93 |
105.0 |
OPTION B - The Hyper Sensitive Method
(For a quick guide, refer to Table 6.)
|
1 |
Dilute the wash buffer concentrate appropriately. |
|
2 |
Equilibrate reagents and samples to room temperature
before use. (Cold reagents will slow down the reaction and
warming up rate will be different from tube to tube.) |
|
3 |
Label test tubes in duplicate for each standard (0 -100
µIU/ml), control serum and patient samples. |
|
4 |
Homogenize all reagents and patient samples by gentle
mixing. Avoid foaming. |
|
5 |
Pipette 200 µl of standards, control and patient samples
into the bottom of labelled tubes. |
|
6 |
Pipette 200 µl of tracer into each tube. Total count
tubes should be set aside for counting. |
|
7 |
Incubate tubes for 45 minutes at room temperature (20–28
°C). |
|
8 |
Vigorously shake and swirl the bottle containing magnetic
immunosorbent until homogeneity is achieved. Add 500 µl MIS to
each tube. Swirl the bottle of MIS after every 15-20 tubes. |
|
9 |
Thoroughly vortex mix all tubes. and incubate them for 15
minutes at room temperature. |
|
10 |
Attach the rack on to the magnetic separator base and
ensure that every tube is in contact with the base plate. Let
the MIS particles settle for 5 minutes. Do not remove the rack
from the separator base after the separation of the solid and
liquid phases. Pour off and discard the supernatant. Keeping the
separator inverted. place the tubes on a pad of absorbent tissue
and allow to drain for 2 minutes. |
|
11 |
Return the separator to an upright position and add 1.0
ml of washing solution to each tube. For more comfort and
precision. it is recommended to use either a repeating pipette
(e.g. Eppendorf pipette) or a dispenser with bottle for the
addition of washing solution. |
|
12 |
Vortex mix each tube thoroughly and repeat Step 10.
Intense vortexing is required. |
|
13 |
Count each tube for at least 60 seconds in a gamma
counter. |
|
14 |
Calculate the TSH concentration of the samples as
described in Calculation of results or use special
software. |
Table
6. Assay Protocol, Pipetting Guide for OPTION B
All volumes are in microliters (µl).
|
Tube |
Total |
Standard |
Sample |
Control |
|
Standard |
|
200 |
|
|
|
Sample |
|
|
200 |
|
|
Control |
|
|
|
200 |
|
Tracer |
(200) |
200 |
200 |
200 |
|
Vortex mix
Incubate for 45 minutes at room temperature |
|
Magnetic immunosorbent |
|
500 |
500 |
500 |
|
Vortex mix
Incubate for 15 minutes at room temperature |
|
Place the tubes on the magnetic separator for 5 minutes. |
|
Decant the fluid and blot on filter paper |
|
Wash Buffer |
|
1000 |
1000 |
1000 |
|
Vortex mix. |
|
Place the tubes on the magnetic separator for 5 minutes. |
|
Decant the fluid and blot on filter paper |
|
Count radioactivity (60 sec/tube) |
|
Calculate the results. |
Characterization of the assay for OPTION B

Figure 2.
OPTION B Typical standard curve corresponding to Table 7.
(Do not use to calculate sample values!)
Table 7.
Typical assay data for OPTION B
| |
CPM
1 |
CPM
2 |
CPM
mean |
B/T % |
|
Total |
408 066 |
405 954 |
407 010 |
- |
|
S0 (NSB) |
54 |
90 |
72 |
0.018 |
|
S0.06 |
478 |
522 |
500 |
0.123 |
|
S0.15 |
895 |
1 037 |
966 |
0.237 |
|
S0.6 |
3 864 |
3 642 |
3 753 |
0.922 |
|
S2.5 |
15 321 |
14 229 |
14 775 |
3.63 |
|
S15 |
82 328 |
84 720 |
83 524 |
20.52 |
|
S50 |
218 273 |
215 871 |
217 072 |
53.33 |
|
S100 (Bmax) |
310 516 |
308 014 |
309 265 |
75.99 |
|
CI |
1 906 |
2 088 |
1 997 |
0.30 |
|
CII |
121 274 |
119 754 |
120 514 |
19.3 |
Sensitivity
The
analytical sensitivity or minimum detectable limit is calculated by
the interpolation of the mean counts of zero standard plus 2 standard
deviation from the standard curve. Determination was carried out using
20 replicates of zero standard response.
The value of
analytical sensitivity is 0.008 µIU/ml measured using fresh tracer.
The
functional sensitivity is a measure of the hTSH concentration that
is significantly different from zero as determined by the inter-assay
precision profile (22% CV).
The value of
functional sensitivity is: 0.05 µIU/ml.
Hook effect
There is no
high dose hook effect up to an hTSH concentration 500 µIU/ml.
Precision
The
within-assay precision was determined with 15 replicates within a single
run. the between-assay precision was estimated in 15 independent runs
carried out in duplicates. CV values are summarized below:
Table 8/1.
| |
intra-assay |
|
sample No. |
mean (µIU/ml) |
CV % |
|
1 |
0.040 |
39.6 |
|
2 |
0.062 |
18.5 |
|
3 |
0.082 |
13.4 |
|
4 |
0.101 |
13.7 |
|
5 |
0.128 |
16.1 |
|
6 |
0.135 |
10.3 |
|
7 |
0.199 |
3.8 |
|
8 |
0.289 |
7.4 |
|
9 |
0.609 |
2.2 |
|
10 |
0.710 |
2.4 |
|
11 |
0.964 |
1.9 |
|
12 |
1.17 |
2.8 |
|
13 |
1.80 |
2.1 |
|
14 |
3.17 |
1.6 |
|
15 |
6.39 |
2.9 |
|
16 |
19.47 |
1.8 |
|
17 |
22.12 |
1.5 |
The
between-assay (inter-assay) precision was determined using pooled human
serum samples in independent assay runs. The number of measurements on a
sample was a function of sample volume available. Three different
operators took part in the investigation process and four different
tracer batches were used at different ages of the reagents. Four
different lots of MIS were used to determine the inter-assay precision
profile. Results are presented below.
Table 8/2.
| |
|
inter-assay |
|
sample No. |
number of assay runs |
mean (µIU/ml) |
CV % |
|
1 |
19 |
0.036 |
28.5 |
|
2 |
19 |
0.061 |
16.7 |
|
3 |
19 |
0.080 |
9.1 |
|
4 |
14 |
0.094 |
7.1 |
|
5 |
20 |
0.118 |
7.1 |
|
6 |
20 |
0.136 |
5.7 |
|
7 |
21 |
0.196 |
6.9 |
|
8 |
21 |
0.284 |
4.5 |
|
9 |
21 |
0.607 |
2.6 |
|
10 |
20 |
0.735 |
3.5 |
|
11 |
20 |
0.988 |
3.6 |
|
12 |
21 |
1.20 |
3.4 |
|
13 |
21 |
1.85 |
3.5 |
|
14 |
21 |
3.14 |
2.5 |
|
15 |
21 |
6.34 |
2.7 |
|
16 |
21 |
19.87 |
2.7 |
|
17 |
21 |
22.89 |
3.2 |
Linearity – dilution test
Individual human serum samples were diluted with the zero standard of
the kit. The diluted samples were measured according to kit protocol.
Table 9.
|
sample
No. |
dilution factor |
expected µIU/ml |
observed µIU/ml |
recovery
% |
|
1 |
1 |
|
12.31 |
|
|
1 |
2.02 |
6.11 |
5.89 |
96.4 |
|
1 |
4.08 |
3.02 |
2.91 |
96.5 |
|
1 |
8.23 |
1.50 |
1.47 |
98.0 |
|
2 |
1 |
|
25.17 |
|
|
2 |
2.02 |
12.48 |
12.24 |
98.1 |
|
2 |
4.05 |
6.22 |
6.07 |
97.7 |
|
2 |
8.14 |
3.09 |
3.01 |
97.4 |
|
3 |
1 |
|
32.81 |
|
|
3 |
1.99 |
16.47 |
15.68 |
95.2 |
|
3 |
3.97 |
8.26 |
7.83 |
94.9 |
|
3 |
7.92 |
4.14 |
3.97 |
95.8 |
|
4 |
1 |
|
12.92 |
|
|
4 |
1.99 |
6.48 |
6.73 |
103.8 |
|
4 |
3.97 |
3.25 |
3.37 |
103.7 |
|
4 |
7.96 |
1.62 |
1.69 |
104.2 |
|
5 |
1 |
|
30.55 |
|
|
5 |
2.03 |
15.06 |
14.48 |
96.1 |
|
5 |
4.12 |
7.42 |
6.54 |
88.1 |
|
5 |
8.33 |
3.67 |
3.29 |
89.7 |
|
6 |
1 |
|
1.43 |
|
|
6 |
2.03 |
0.705 |
0.687 |
97.5 |
|
6 |
4.10 |
0.349 |
0.341 |
97.8 |
|
6 |
8.33 |
0.172 |
0.158 |
92.0 |
|
7 |
1 |
|
22.99 |
|
|
7 |
2.00 |
11.46 |
11.74 |
102.4 |
|
7 |
4.04 |
5.69 |
5.87 |
103.1 |
|
7 |
8.12 |
2.83 |
2.91 |
102.8 |
|
8 |
1 |
|
0.867 |
|
|
8 |
2.02 |
0.429 |
0.411 |
95.9 |
|
8 |
4.09 |
0.212 |
0.195 |
92.0 |
|
8 |
8.25 |
0.105 |
0.092 |
87.5 |
|
9 |
1 |
|
1.88 |
|
|
9 |
2.00 |
0.938 |
0.930 |
99.1 |
|
9 |
4.00 |
0.470 |
0.472 |
100.5 |
|
9 |
8.00 |
0.235 |
0.233 |
99.3 |
|
10 |
1 |
|
14.13 |
|
|
10 |
2.02 |
7.01 |
7.08 |
101.0 |
|
10 |
4.05 |
3.49 |
3.57 |
102.3 |
|
10 |
8.18 |
1.73 |
1.69 |
98.0 |
Recovery – addition test
Individual human serum samples were spiked with known amount of an
elevated stock sample. Recovery % is to be interpreted as =
(observed-base)/added*100. The results are summarized below.
Table 10.
|
sample |
basic
µIU/ml |
added
µIU/ml |
expected µIU/ml |
observed µIU/ml |
recovery
% |
|
1 |
0.916 |
14.80 |
15.72 |
13.75 |
86.7 |
|
2 |
0.613 |
14.59 |
15.21 |
13.50 |
88.3 |
|
3 |
1.02 |
14.69 |
15.71 |
13.87 |
87.5 |
|
4 |
0.809 |
14.77 |
15.58 |
14.18 |
90.5 |
|
5 |
1.86 |
14.44 |
16.30 |
15.48 |
94.4 |
|
6 |
0.215 |
2.90 |
3.11 |
3.40 |
110.0 |
|
7 |
0.006 |
2.77 |
2.78 |
2.95 |
106.3 |
|
8 |
0.007 |
2.82 |
2.83 |
3.04 |
107.6 |
|
9 |
0.025 |
2.85 |
2.88 |
3.09 |
107.4 |
|
10 |
0.032 |
2.77 |
2.80 |
3.34 |
119.4 |
|
11 |
0.126 |
3.78 |
3.90 |
4.23 |
108.5 |
|
12 |
0.076 |
2.86 |
2.93 |
3.09 |
105.5 |
|
13 |
0.024 |
3.24 |
3.26 |
3.35 |
102.7 |
|
14 |
0.062 |
2.82 |
2.89 |
3.39 |
117.9 |
|
15 |
0.011 |
2.87 |
2.88 |
3.05 |
106.0 |
|
16 |
0.027 |
3.11 |
3.14 |
3.28 |
104.6 |
|
17 |
0.001 |
3.56 |
3.56 |
3.80 |
106.9 |
|
18 |
0.042 |
2.78 |
2.82 |
2.99 |
106.1 |
|
19 |
0.007 |
3.51 |
3.52 |
3.64 |
103.5 |
|
20 |
0.004 |
2.78 |
2.78 |
2.94 |
105.8 |
|
21 |
0.003 |
3.27 |
3.27 |
3.50 |
106.9 |
|
22 |
0.011 |
2.76 |
2.77 |
3.02 |
108.9 |
|
23 |
0.916 |
14.80 |
15.72 |
13.75 |
86.7 |
Option independent data
Specificity
No cross
reactivity with hFSH and hTSH can be detected in normal physiological
concentrations. 2 000 mIU/ml hCG gives an apparent 3.5 µIU/ml increase
in hTSH concentration.
Expected Values
Expected
euthyroid range is 0.25 µIU/ml - 3.55 µIU/ml.
It is
recommended that each laboratory determine a reference range for
euthyroids for its own patient population. since this may vary in
different laboratories or regions.
Calculation of results
The
calculation is illustrated using representative data. The assay data
collected should be similar to those shown in Table 2 / 7.
Calculate the average count per minute (cpm) for each pair of assay
tubes. Calculate the normalized percent binding for each standard,
control and sample respectively by using the following equation:
| |
Standard [Control, Sample] (cpm) |
|
|
B / T (%) = |
———————————— |
x 100 |
| |
T (cpm) |
|
Using
logarithmic graph paper plot B/T (%) for each standard versus the
corresponding concentration of hTSH.
Determine the
hTSH concentration of the controls & unknown samples by interpolation
from the standard curve. Automated data processing systems are also
applicable.
Additional information
Components from various lots or from kits of different manufacturers
should not be mixed or interchanged.
Precaution
Radioactivity
This product
contains radioactive material. It is the responsibility of the user to
ensure that local regulations or code of practice related to the
handling of radioactive materials are satisfied.
Biohazard
Human
blood products used in the kit have been obtained from healthy human
donors. They were tested individually by using approved methods (EIA.
enzyme immunoassay). and were found to be negative. for the presence of
both Human Immunodeficiency Virus antibody (Anti-HIV-1) and Hepatitis B
surface Antigen (HBsAg).
Care
should always be taken when handling human specimens to be tested with
diagnostic kits. Even if the subject has been tested. no method can
offer complete assurance that Hepatitis B Virus. Human Immunodeficiency
Virus (HIV-1) or other infectious agents are absent. Human blood samples
should therefore be handled as potentially infectious materials.
Chemical
hazard
Components contain sodium azide as an antimicrobial agent. Dispose of
waste by flushing with copious amount of water to avoid build-up of
explosive metallic azides in copper and lead plumbing. The total azide
present in each pack is 74 mg.
 |
Use by |
 |
In vitro diagnostic medical device |
 |
Control |
 |
Batch code |
 |
Manufacturer |
 |
Standard |
 |
Caution, consult accompanying documents |
 |
Radioactive material |
 |
Magnetic immunosorbent |
 |
Biological risk |
 |
Temperature limitation
Store between 2-8 °C |
 |
Tracer |
 |
Consult operating instructions |
 |
Catalogue number |
 |
Wash buffer |

|